Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
This study has been completed.
Information provided by:
First received: September 9, 2002
Last updated: June 23, 2005
Last verified: May 2004
The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Celgene Corporation:
Contacts and Locations